Centchroman

Alternative Name: Saheli; Ormeloxifene

Description: A non-hormonal oral contraceptive available only in India. It is a selective estrogen receptor modulator (SERM). It is also used for management of abnormal uterine bleeding (AUB) and as an emergency contraceptive, in addition to use as a weekly contraceptive.

Product Details

User: Female

Hormonal: No

Delivery Method: Oral

Duration Type: Short-acting, Emergency

Duration: One week

Regimen:
  • weekly

Dose: 30 mg

Active Pharmaceutical Ingredient (API):
  • ormeloxifene

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Central Drug Research Institute, India, HLL Lifecare Limited

Project Phase: Limited Market Availability

Development Stage: Marketed

Began discovery in: 1977

Active Development: Yes

Status Details:
  • Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years.
  • In one trial centchroman was shown to induce apoptosis in human breast cancer cells. Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.

Additional Information

References:
  • HLL website: http://www.lifecarehll.com/product/view/reference/698d51a19d8a121ce58149...

  • Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 21(4): 302-47.

  • Kamboj VP, Ray S, Anand N. Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front BioSci. 2018 Jan 1; 10:1-14.

  • Dewangan J, Kaushik S, Rath SK, Balapure AK. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1a/VEGFR signaling axis. LifeSci 2018 Jan 15. 193:9-19.

Vertical Tabs

Print